Featuring an interview with Dr Jeremy Abramson, including the following topics:
- Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00)
- Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31)
- Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associated neurotoxicity syndrome) and infectious complications in patients with CLL (6:21)
- Available data with bispecific antibodies for CLL (9:38)
- Sequencing CAR T-cell therapy and pirtobrutinib for patients with previously treated CLL (11:09)
- Integrating bispecific antibodies into community-based practice; strategies for mitigating associated toxicities (14:25)
- CD20 versus CD19 as a therapeutic target in lymphomas (20:31)
- First-line treatment selection for patients with mantle cell lymphoma (23:07)
- Chemotherapy combined with nivolumab or with brentuximab vedotin as initial therapy for Hodgkin lymphoma (30:12)
CME information and select publications
Research To Practice | Oncology Videos